|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Kaiso/p120-Catenin and TCF/β-Catenin Complexes Coordinately Regulate Canonical Wnt Gene Targets显示文摘 | Jae-il Park Si Wan Kim Jon P. Lyons Hong Ji Thi T. Nguyen Kyucheol Cho Michelle C. Barton Tom Deroo Kris Vleminckx Pierre D. McCrea | 2005 | Developmental Cell2005，，： | 1 |
| 2 | TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice显示文摘 | Shiming Jiang Lindsey Cauthen Minter Sabrina A. Stratton Peirong Yang Hussein A. Abbas Zeynep Coban Akdemir Vinod Pant Sean Post Mihai Gagea Richard G. Lee Guillermina Lozano Michelle Craig Barton | 2014 | Journal of Hepatology2014，，： | 1 |
| 3 | Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial显示文摘 | William J Marks Raymond T Bartus Joao Siffert Charles S Davis Andres Lozano Nicholas Boulis Jerrold Vitek Mark Stacy Dennis Turner Leonard Verhagen Roy Bakay Raymond Watts Barton Guthrie Joseph Jankovic Richard Simpson Michele Tagliati Ron Alterman Matthe | 2010 | Lancet Neurology2010，，12： | 1 |
| 4 | 锌指蛋白ZBTB20是调控肝脏甲胎蛋白基因转录的关键抑制因子显示文摘甲胎蛋白(AFP)在胎肝中高表达,出生后不久就快速下调至很低水平。有关肝脏AFP基因出生后的转录抑制机制一直是未解之谜。AFP基因的增强子、抑制区域和启动子等顺式调控元件可能参与其转录抑制的调节,但有关的关键性转录抑制因子尚不明确。我们发现了一种新型锌指蛋白ZBTB20,为研究其体内的生理功能,我们利用条件打靶技术,建立了ZBTB20的组织特异性基因敲除小鼠模型,发现肝细胞特异性ZBTB20基因敲除小鼠出生后的肝脏AFP基因一直维持近乎胎肝的高水平表达,而其肝细胞处于正常的静息状态。生化分析显示,ZBTB20具有转录抑制活性,体外可有效抑制AFP启动子的转录活性;染色质免疫沉淀和EMSA实验结果显示ZBTB20体内和体外能直接结合AFP启动子。在小鼠肝脏的发育过程中,ZBTB20基因被渐进激活,与AFP基因的表达水平呈负相关,提示激活的ZBTB20参与了AFP基因的转录抑制。上述结果表明ZBTB20是调控AFP基因表达的关键转录因子,由此我们认为肝脏ZBTB20基因出生后的表达上调及其发挥的转录抑制作用是导致AFP基因出生后快速下调的主要原因。 | 谢志芳 张海 Wenwei Tsai 张晔 杜宇 钟纪根 Claude Szpirer 朱明华 曹雪涛 Michelle Craig Barton Michael J. Grusby 章卫平 | 2008 | 第二军医大学学报2008，29，9： | 0 |
| 5 | Comparison of pediatric ventriculoperitoneal shunt infections arising in antibiotic-impregnated and standard catheters:a multicenter observational study显示文摘Antibiotic-impregnated ventricular shunt catheters(AIVSCs)with 0.15%clindamycin and 0.054%rifampin are commonly used to prevent ventriculo-peritoneal(VP)shunt infections.Initially approved by the United States Food and Drug Administration in 2003(https://www.integralife.com/file/general/1561404015.pdf),they have antimicrobial activity documented for minimum 31 days(https://www.accessdata.fda.gov/cdrh_docs/pdf11/K110560.pdf).These antibiotics were chosen as they cover the majority of Staphylococcus aureus and may provide some activity against coagulase negative staphylococci.1 These normal skin flora account for the majority of VP shunt infections.In the largest randomized controlled trial(RCT)to date,AIVSCs significantly reduced the risk of infection compared with standard shunts(cause-specific hazard ratio(HR)0.38).2 This effect was mainly due to a reduction in staphylococcal infections;the number of gram-negative infections was similar in both groups.Observational studies3–5 and a meta-analysis6 in children support the findings of this RCT.The objective of this study was to examine the spectrum of pathogens,time to infection,and outcomes with AIVSCs vs standard shunts. | Joan Robinson Archana Balamohan Michelle Barton Marie-Astrid Lefebvre Ahmed Almadani Dolores Freire Alastair McAlpine Jocelyn Srigley Patrick Passarelli John Bradley Dele Davies Gwenn Skar Isabelle Viel-Theriault Sarah Khan Rupeena Purewal Nicole LeSaux Jennifer Bowes Michael Hawkes 无 | 2023 | World Journal of Pediatric Surgery2023，6，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员